FDA
FDA Articles
Progenics Pharmaceuticals shares took a big step back on Friday after the firm announced that it received an update from the FDA.
Published:
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Published:
Last Updated:
Solid Biosciences Inc. (NASDAQ: SLDB) watched its shares get crushed on Thursday after the company announced some complications with the U.S. Food and Drug Administration (FDA). Specifically, the FDA...
Published:
Last Updated:
Proteostasis Therapeutics saw its shares skyrocket going into Tuesday’s session following a pivotal decision from the FDA for the firm’s cystic fibrosis therapy.
Published:
Last Updated:
24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of March.
Published:
Last Updated:
Celgene watched its shares drop on Wednesday after the company announced that it received a Refusal to File letter from the FDA.
Published:
Last Updated:
Here 24/7 Wall St. has included a calendar of a few of the biggest companies expecting clinical trial and FDA updates in February.
Published:
Last Updated:
AMAG Pharmaceuticals saw its shares skyrocket early on Thursday after the company announced that it received an FDA approval.
Published:
Last Updated:
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
Published:
Last Updated:
Johnson &; Johnson, Gilead Sciences and Amicus Therapeutics are among companies expecting clinical trial and FDA updates in February.
Published:
Last Updated:
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Published:
Last Updated:
Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.
Published:
Last Updated:
Atara Biotherapeutics shares surged on Friday after the firm announced that it received clearance from the FDA to initiate two Phase 3 clinical studies.
Published:
Last Updated:
Although Shire is not seeing much of a bump in its share price, the firm is creating a lot of value with its most recent submission to the FDA.
Published:
Last Updated:
Paratek Pharmaceuticals saw its shares make a handy gain on Thursday after the firm announced that the FDA accepted its New Drug Application for the review of Seysara for the treatment of moderate to...
Published:
Last Updated: